In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from third-party sources, including reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. Segment and End Market CY22 % of Revenue You should not rely on these for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Delaware 83-0974996 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi ...

MIRITO N TECHNOLOGIES MIR LISTED NYSE Fiscal Third Quarter Ended September 30, 2022 Earnings Presentation November 1, 2022 Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "continue," "could," "estimate", "expect", "hope", "intend", "may", "might", "should", "would", "will", "understand" and similar words a ...

Mirion Technologies, Inc. (NYSE:MIR) Q3 2022 Results Conference Call November 1, 2022 4:30 PM ET Company Participants Alex Gaddy - VP, Head of Strategy & Corporate Development Larry Kingsley - Chairman of the Board Tom Logan - Chief Executive Officer Brian Schopfer - Chief Financial Officer Conference Call Participants Joe Ritchie - Goldman Sachs Chris Moore - CJS Securities Andy Kaplowitz - Citigroup Operator Greetings. And welcome to Mirion Technologies Inc. Third Quarter 2022 Earnings Conference Call. At ...

Jefferies Industrials Conference August 10, 2022 New York, NY The Energy of Innovation © 2022 Mirion Technologies. All rights reserved. Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "continue," "could," "estimate", "expect", "hope", "intend", "may", "might", "should", "would", "will", "understand" and si ...

Financial Performance - Total revenues for Q2 2022 were $175.8 million, a decrease of 2.3% compared to $180.0 million in Q2 2021[24]. - Product revenues decreased to $130.3 million in Q2 2022 from $141.0 million in Q2 2021, representing a decline of 4.9%[24]. - Service revenues increased to $45.5 million in Q2 2022, up 16.7% from $39.0 million in Q2 2021[24]. - The company reported a net loss of $58.6 million for the three months ended June 30, 2022, compared to a net loss of $53.9 million for the same period in 2021[157]. - For the six months ended June 30, 2022, total revenues were $339.0 million, a decrease of 2.1% from $346.2 million in the same period of 2021[148]. - The company experienced a net loss of $59.3 million for the three months ended June 30, 2022, compared to a net loss of $54.0 million for the same period in 2021, representing an increase in losses of approximately 9.8%[196]. - Net loss for the six months ended June 30, 2022, improved to $78.3 million from a loss of $94.7 million in the same period of 2021, representing a 17.5% reduction[199]. Expenses and Profitability - Gross profit for Q2 2022 was $79.0 million, slightly down from $79.6 million in Q2 2021[24]. - Operating expenses surged to $153.6 million in Q2 2022, compared to $74.9 million in Q2 2021, primarily due to a $55.2 million goodwill impairment[24]. - Selling, general and administrative expenses increased to $91.0 million in the Successor Period from $66.7 million in the Predecessor Period, reflecting a rise of 36.5%[216]. - Adjusted EBITDA for the three months ended June 30, 2022, was $42.6 million, down from $49.9 million in the same period of 2021, indicating a decline of about 6.3%[196]. - Adjusted EBITDA for the six months ended June 30, 2022, was $77.5 million, down 13.4% from $89.9 million in the same period of 2021[204]. Assets and Liabilities - Total assets decreased to $2,916.9 million as of June 30, 2022, down from $3,118.0 million at the end of 2021[22]. - Total liabilities were $1,258.0 million as of June 30, 2022, a decrease from $1,334.0 million at the end of 2021[22]. - Stockholders' equity decreased to $1,658.9 million as of June 30, 2022, down from $1,784.0 million at the end of 2021[22]. - Total accrued expenses and other current liabilities amounted to $73.6 million as of June 30, 2022, a decrease from $75.4 million at December 31, 2021[70]. Goodwill and Impairments - The company incurred a goodwill impairment of $55.2 million during the six months ended June 30, 2022[34]. - The total goodwill balance decreased to $1,566.6 million from $1,662.6 million as of December 31, 2021, reflecting a goodwill impairment of $55.2 million in the Industrial segment[79]. - A goodwill impairment charge of $55.2 million was recorded in the Industrial segment during the Successor Period[218]. Segment Performance - Medical segment revenues for the three months ended June 30, 2022, were $66.8 million, up from $52.1 million in the prior year[145]. - Industrial segment revenues for the three months ended June 30, 2022, were $109.0 million, down from $127.9 million in the same period of 2021[145]. - Medical segment revenues for the six months ended June 30, 2022, were $126.9 million, while Industrial segment revenues were $212.1 million[204]. Cash Flow and Liquidity - Operating cash flow for the six months ended June 30, 2022, was $28.0 million, down from $33.7 million in the prior year, indicating a decrease of 16.9%[34]. - Cash, cash equivalents, and restricted cash at the end of the period were $92.0 million, up from $85.3 million at the beginning of the period, marking an increase of 7.8%[34]. - Cash paid for interest during the six months ended June 30, 2022, was $13.9 million[126]. Backlog and Future Outlook - The backlog as of June 30, 2022, was $692.7 million, a decrease from $747.5 million as of December 31, 2021[185]. - The company plans to continue focusing on expanding its medical segment and enhancing its product offerings in the upcoming quarters[148]. - The company has a backlog driven by contracts for new nuclear power plant construction, providing a strong pipeline for future revenue recognition in the Industrial segment[190]. Other Financial Metrics - The effective income tax rate for the three months ended June 30, 2022, was 11.1%, compared to (36.4)% for the same period in 2021[124]. - The company recognized an unrealized gain of $39.5 million due to a decrease in the fair value of warrant liabilities for the six months ended June 30, 2022[155]. - The fair value of public warrants was measured at $19.7 million as of June 30, 2022, based on the listed market price[153].

Mirion Technologies, Inc. (NYSE:MIR) Q2 2022 Earnings Conference Call July 29, 2022 10:00 AM ET Company Participants Alex Gaddy - Vice President, Finance & Investor Relations Larry Kingsley - Chairman Tom Logan - Chief Executive Officer Brian Schopfer - Chief Financial Officer Conference Call Participants Andy Kaplowitz - Citigroup Joe Ritchie - Goldman Sachs Chris Moore - CJS Securities Operator Greetings. Welcome to Mirion Technologies Incorporated Fiscal Second Quarter 2022 Earnings Conference Call. At t ...

MIRION TECHNOLOGIES MIR LISTED NYSE Fiscal Second Quarter Ended June 30, 2022 Earnings Presentation July 29, 2022 Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "continue," "could," "estimate", "expect", "hope", "intend", "may", "might", "should", "would", "will", "understand" and similar words are intend ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39352 Mirion Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 83-0974996 (State or ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $163.2 million, representing a decline of 4.3% compared to Q1 2021, with adjusted EBITDA down 12.5% [24][25] - Organic revenue declined by 4.2%, with adjusted EBITDA margin contracting by 200 basis points to 21.4% [24][25] - Adjusted EPS for the quarter was $0.10, slightly better than expectations due to lower taxes [25] Business Line Data and Key Metrics Changes - Medical segment adjusted revenue increased by 7.7%, with organic growth of 0.7%, but was negatively impacted by supply chain challenges [26] - Industrial segment reported a 10.1% decline in adjusted revenue, with organic revenue down 6.6% [27] - Strong growth in nuclear medicine and dosimetry was noted, but overall performance was offset by supply chain disruptions [21][26] Market Data and Key Metrics Changes - Core orders grew approximately 19% year-over-year, adjusted for foreign exchange impacts, indicating robust demand across both industrial and medical segments [12][33] - The outlook for the nuclear power industry has improved, with increased government support and rising natural gas prices driving demand [12][15] - The defense segment is expected to see increased demand due to heightened military and civil defense concerns stemming from the Ukraine conflict [16][17] Company Strategy and Development Direction - The company aims to deliver inorganic growth of 5 to 10 points and has a strong M&A pipeline [22] - Focus on digitization and new product launches in the medical segment, including the introduction of SunCHECK and SunSCAN [18] - The company has removed all remaining Russian-related revenue from projections, reflecting a cautious approach to geopolitical dynamics [20] Management's Comments on Operating Environment and Future Outlook - The operating environment remains challenging due to supply chain issues and geopolitical tensions, but the company is well-positioned for growth [6][9] - Management expressed confidence in the ability to navigate short-term hurdles, citing a strong backlog and healthy end markets [22][33] - Future growth is expected to be supported by favorable market conditions in nuclear power and defense sectors [12][15][16] Other Important Information - The company generated $10 million of adjusted free cash flow in Q1 2022, a slight improvement from the previous year [28] - Updated guidance for 2022 reflects a revised adjusted revenue growth expectation of 3.5% to 5.5%, down from 5.5% to 7.5% [29][30] - Adjusted EBITDA target range for 2022 has shifted to $170 million to $180 million, reflecting the removal of Russian-related EBITDA [30][31] Q&A Session Summary Question: Supply chain challenges in the Medical segment - Management confirmed that supply chain issues have shifted towards radiation therapy and nuclear medicine, with proactive measures in place to address these challenges [36] Question: Pricing escalators in contracts - Management indicated that most contracts have pricing escalators, but there is a lag in price adjustments, with expectations for improvement in the latter half of the year [37][38] Question: New construction's impact on nuclear revenue - Management expects the percentage of revenue from new construction to increase due to favorable conditions in the nuclear industry [40] Question: Incremental defense and nuclear EBITDA - Management provided insights into the expected $10 million increase in defense and nuclear EBITDA, citing strong order dynamics and government support [46][65] Question: Order trends and conversion into earnings - Management noted that the 19% growth in core orders reflects strength across segments, with expectations for gradual conversion into earnings over the coming quarters [50][63] Question: Cash flow generation and leverage - Management emphasized a focus on generating cash flow to tackle leverage, with expectations for improved cash generation in the latter half of the year [72] Question: Direct exposure to supply chain issues in China - Management clarified that direct exposure to China is limited, with proactive measures in place to mitigate supply chain risks [74]